AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23901678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride 1mg thrice daily 15 minutes before meals for 4 weeks
Number of subjects: 121
Study 20363044 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 155
Study 20363044 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 155
Study 18440347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 4162
Study 18440347 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg daily
Number of subjects: 4162
Study 19968382 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief experiential psychotherapy
Number of subjects: 74
Study 19968382 — intervention group
Group type: EXPERIMENTAL
Intervention: Beginning therapy alliance (after Session 1)
Number of subjects: 74
Study 19968382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients' beginning therapy process
Number of subjects: 74
Study 15885904 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (familiarized with procedures)
Number of subjects: 22
Study 15885904 — intervention group
Group type: COMPARATOR
Intervention: Group B (received only verbal instructions)
Number of subjects: 22
Study 15885904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 11472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0
Study 11472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 0
Study 11472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 11472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogues (general)
Number of subjects: 0
Study 9455271 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam dressing
Number of subjects: 61
Study 9455271 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 61
Study 9455271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 61
Study 8188798 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention in first grade and middle school
Number of subjects: 1000
Study 3115841 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine monohydrochloride (1,000 mg per dose, 3 times a day for 6 months)
Number of subjects: 52
Study 3115841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31916789 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management (IY TCM)
Number of subjects: 1817
Study 31916789 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison group (Control)
Number of subjects: 1817
Study 30710652 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine and calcium carbonate in-office prophylaxis paste and respective toothpaste
Number of subjects: 273
Study 30710652 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free prophylaxis paste and sodium monofluorophosphate toothpaste
Number of subjects: 273
Study 30146649 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching
Number of subjects: 43
Study 30146649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 43
Study 27020947 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based cluster randomised trial (CRT)
Number of subjects: 20
Study 25039273 — intervention group
Group type: COMPARATOR
Intervention: LY3000328 (up to 300 mg)
Number of subjects: 21
Study 25039273 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3000328
Number of subjects: 21
Study 22503610 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker + calcium channel blocker
Number of subjects: 1164
Study 22503610 — intervention group
Group type: COMPARATOR
Intervention: High-dose angiotensin II receptor blocker (40 mg/d olmesartan)
Number of subjects: 1164
Study 19459794 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF(CC) and reduced-level calcineurin inhibitor (MMF(CC)/CNI(RL))
Number of subjects: 720
Study 19459794 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF(CC) and standard-level CNI (MMF(CC)/CNI(SL))
Number of subjects: 720
Study 19459794 — intervention group
Group type: COMPARATOR
Intervention: fixed-dose MMF and CNI(SL) (MMF(FD)/CNI(SL))
Number of subjects: 720
Study 17514528 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized aspheric algorithm (32 patients, group A)
Number of subjects: 58
Study 17514528 — intervention group
Group type: COMPARATOR
Intervention: Conventional algorithm (26 patients, group B)
Number of subjects: 58
Study 15479685 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient oriented self management approach
Number of subjects: 700
Study 15479685 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient oriented self management training
Number of subjects: 700
Study 15479685 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 700
Study 11476427 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake (VO2peak) measured in boys and girls
Number of subjects: 195
Study 11476427 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric regression standards with sexes separated
Number of subjects: 195
Study 11476427 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat increase in girls during puberty
Number of subjects: 195
Study 11476427 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2peak expressed as ml kg(‐1) min(‐1)
Number of subjects: 195
Study 9631839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 1919
Study 7932683 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback, imagery, and breathing training for 5 weeks
Number of subjects: 84
Study 7932683 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 7932683 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment subjects
Number of subjects: 84
Study 2962876 — intervention group
Group type: EXPERIMENTAL
Intervention: Human atrial natriuretic peptide (hANP: 50 micrograms h‐1 for 6 h)
Number of subjects: 6
Study 2962876 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE: 50 ng kg‐1 min‐1)
Number of subjects: 6
Study 29883885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous paracetamol every 4 h for 72 h
Number of subjects: 0
Study 29883885 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride every 4 h for 72 h
Number of subjects: 0
Study 27841759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,400 IU/day)
Number of subjects: 881
Study 27841759 — intervention group
Group type: COMPARATOR
Intervention: Control group (400 IU/day)
Number of subjects: 881
Study 27841759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient vitamin D status (25OHD ≥30 ng/ml)
Number of subjects: 881
Study 27841759 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential expression of vitamin D‐associated genes
Number of subjects: 881
Study 25134364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass Carbomer sealant (group B)
Number of subjects: 24
Study 25134364 — intervention group
Group type: COMPARATOR
Intervention: Resin-based sealant (group A)
Number of subjects: 24
Study 25134364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 23528262 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 379
Study 23528262 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 379
Study 23528262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year ATRA
Number of subjects: 379
Study 23528262 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 379
Study 20585969 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose fosfomycin trometamol (FMT) 3 g
Number of subjects: 260
Study 20585969 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice a day for 5 days
Number of subjects: 260
Study 19008768 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery for brain AVMs
Number of subjects: 30
Study 16323126 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial treatment (specific regimens not detailed)
Number of subjects: 1965
Study 16323126 — intervention group
Group type: EXPERIMENTAL
Intervention: New infections (molecular genotyping)
Number of subjects: 1965
Study 16323126 — intervention group
Group type: EXPERIMENTAL
Intervention: Recrudescences (molecular genotyping)
Number of subjects: 1965
Study 15456051 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive transverse forces (PTF) applied on the deformed body, 4 to 6 treatments lasting 20 minutes each, combined with intensive rehabilitation.
Number of subjects: 126
Study 15456051 — intervention group
Group type: COMPARATOR
Intervention: Control group with intensive inpatient rehabilitation alone.
Number of subjects: 126
Study 15456051 — intervention group
Group type: EXPERIMENTAL
Intervention: PTF treatment without additional braces (n=52).
Number of subjects: 126
Study 15456051 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation alone (control group without brace).
Number of subjects: 126
Study 15321153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 degrees head-up position
Number of subjects: 100
Study 15321153 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 100
Study 7742155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours after a standard supper
Number of subjects: 37
Study 7742155 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting (eating a standard supper, snacks, breakfast, and lunch)
Number of subjects: 37
Study 7742155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours
Number of subjects: 37
Study 2038216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerosis
Number of subjects: 46
Study 2038216 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic sclerosis)
Number of subjects: 46
Study 7197959 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (2 times 25 mg)
Number of subjects: 20
Study 7197959 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine (2 times 5 mg)
Number of subjects: 20
Study 7197959 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 20
Study 7197959 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine
Number of subjects: 20
Study 28834330 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music during the procedure
Number of subjects: 62
Study 28834330 — intervention group
Group type: COMPARATOR
Intervention: No music during the procedure
Number of subjects: 62
Study 28682461 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of 5-year stroke risk graphic
Number of subjects: 968
Study 28682461 — intervention group
Group type: COMPARATOR
Intervention: Presentation of 1-year stroke risk graphic
Number of subjects: 968
Study 28682461 — intervention group
Group type: COMPARATOR
Intervention: Physician prescribing to themselves
Number of subjects: 968
Study 26408012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intensity-modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) for 6 months
Number of subjects: 0
Study 26408012 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23631604 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM pre‐CSII
Number of subjects: 16
Study 23631604 — intervention group
Group type: COMPARATOR
Intervention: CGM post‐CSII
Number of subjects: 16
Study 21542927 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 103
Study 21542927 — intervention group
Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 103
Study 19587583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17174640 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose
Number of subjects: 68
Study 17174640 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose
Number of subjects: 68
Study 15204628 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterstereotype information
Number of subjects: 149
Study 15204628 — intervention group
Group type: COMPARATOR
Intervention: Stereotype information
Number of subjects: 149
Study 15204628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 16206677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine (intravenous or intra-muscular injection and oral capsule)
Number of subjects: 303
Study 16206677 — intervention group
Group type: COMPARATOR
Intervention: Tiopronin (control group)
Number of subjects: 303
Study 9872196 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 microg by metered‐dose inhaler)
Number of subjects: 78
Study 9872196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 7884169 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tripotassium dicitrato bismuthate 125 mg q.i.d., tetracycline hydrochloride 500 mg q.i.d., metronidazole 500 mg t.i.d.)
Number of subjects: 245
Study 2403730 — intervention group
Group type: COMPARATOR
Intervention: Non-Q-wave AMI
Number of subjects: 544
Study 2403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to Q-wave AMI
Number of subjects: 544
Study 2403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to Q-wave AMI within 48 hours
Number of subjects: 544
Study 2403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to Q-wave AMI after 48 hours
Number of subjects: 544
Study 344157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times daily
Number of subjects: 23
Study 344157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg four times daily
Number of subjects: 23
Study 344157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30122911 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue exercise group (LG)
Number of subjects: 40
Study 30122911 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 30122911 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LG and CG
Number of subjects: 40
Study 26997377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education for 12 weeks
Number of subjects: 99
Study 26997377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study 25120315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion from calcineurin inhibitors (CNI)
Number of subjects: 45
Study 23194491 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg oral)
Number of subjects: 196
Study 23194491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 20184605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for grass pollen; specific details on dosage and duration not provided.
Number of subjects: 31
Study 20184605 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment; specific details on dosage and duration not provided.
Number of subjects: 31
Study 19192804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at approximately 100 microg/m3
Number of subjects: 0
Study 19192804 — intervention group
Group type: COMPARATOR
Intervention: Purified air
Number of subjects: 0
Study 15785883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (100 mg) added to Tisseel-VH fibrin sealant
Number of subjects: 75
Study 15785883 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure of the primary opening
Number of subjects: 75
Study 15785883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Cefoxitin + Surgical closure)
Number of subjects: 75
Study 14728086 — intervention group
Group type: COMPARATOR
Intervention: Oral ziprasidone
Number of subjects: 0
Study 10532523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin lingual spray
Number of subjects: 0
Study 10532523 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin sublingual tablet
Number of subjects: 0
Study 8889304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 9
Study 8889304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 9
Study 8889304 — intervention group
Group type: COMPARATOR
Intervention: Histamine (control)
Number of subjects: 9
Study 1909749 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TN)
Number of subjects: 112
Study 1909749 — intervention group
Group type: COMPARATOR
Intervention: Long-acting oral nitrates (LAON)
Number of subjects: 112
Study 6344297 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy without drainage (PGV)
Number of subjects: 40
Study 6344297 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy, antrectomy, and gastroduodenostomy (SVA)
Number of subjects: 40
Study 3859027 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures focused on oral hygiene and/or fluorides
Number of subjects: 95
Study 31118485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention involving a face-to-face meeting (medication review and consumer-centred video) and health coaching every two weeks
Number of subjects: 71
Study 31118485 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 30033445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 341
Study 30033445 — intervention group
Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 341
Study 30033445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 341
Study 27416546 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical furosemide (300 µg per day, 2 puffs twice a day for 2 months)
Number of subjects: 84
Study 27416546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 25152604 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion combined with acupuncture
Number of subjects: 92
Study 25152604 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran-partitioned moxibustion combined with superficial acupuncture
Number of subjects: 92
Study 21994026 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with manual manipulation (manipulation group)
Number of subjects: 120
Study 21994026 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture without manipulation (non-manipulation group)
Number of subjects: 120
Study 20493474 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐E2 1 mg/drospirenone 2 mg
Number of subjects: 100
Study 20493474 — intervention group
Group type: COMPARATOR
Intervention: 17β‐E2 1 mg/norethisterone acetate 0.5 mg
Number of subjects: 100
Study 18634941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement (scaling and root planing)
Number of subjects: 67
Study 15616757 — intervention group
Group type: EXPERIMENTAL
Intervention: I.M. testovirone depot 100 mg monthly for 6 months
Number of subjects: 45
Study 15616757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 5 mg/m2 daily for 6 months
Number of subjects: 45
Study 15616757 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 45
Study 14499778 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype wide angle colonoscope
Number of subjects: 70
Study 14499778 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 70
Study 10941955 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on asthma treatment
Number of subjects: 24
Study 10941955 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on UTI treatment
Number of subjects: 24
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 195
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT)
Number of subjects: 195
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual-hormone binding globulin (SHBG)
Number of subjects: 195
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA)
Number of subjects: 195
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone/DHT ratio
Number of subjects: 195
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis on T-stage, PSA level and DHT
Number of subjects: 195
Study 8814852 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 195
Study 1533266 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-Belt (WB)
Number of subjects: 5
Study 1533266 — intervention group
Group type: COMPARATOR
Intervention: Without Belt (WOB)
Number of subjects: 5
Study 6376291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU and methyl CCNU
Number of subjects: 52
Study 6376291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early treatment)
Number of subjects: 52
Study 30726394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolsa Família Programme (PBF)
Number of subjects: 1133
Study 30726394 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Health Strategy (FHS)
Number of subjects: 1133
Study 27003392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 69
Study 27003392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27513246 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (n=998)
Number of subjects: 2001
Study 27513246 — intervention group
Group type: COMPARATOR
Intervention: Nonmigraineurs (n=1003)
Number of subjects: 2001
Study 27513246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2001
Study 25129884 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa damascene aromatherapy for three subsequent nights
Number of subjects: 60
Study 25129884 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 22624890 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior stromal pocket hydration
Number of subjects: 48
Study 22624890 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydration
Number of subjects: 48
Study 20553645 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1 %
Number of subjects: 40